How long is ibrutinib’s FDA exclusivity after approval?
The exact FDA exclusivity period for ibrutinib depends on which FDA “exclusivity” protection you mean (New Chemical Entity, biologic exclusivity, patent term, or other regulatory exclusivities). The information provided here does not include the specific exclusivity category or the approval date needed to calculate the time window.
When does ibrutinib’s exclusivity expire (and why dates can differ)?
Exclusivity and patent protection often get confused. Even if FDA exclusivity ends on a certain date, generic entry can still be delayed by remaining Orange Book patents (or vice versa). To pinpoint an “expiration” date for ibrutinib, you typically need:
- the original FDA approval date, and
- the specific exclusivity type (or the specific FDA-protected formulation/labeling).
Where to check the specific ibrutinib FDA exclusivity info (fastest way)
A reliable way to find the date ranges tied to regulatory protection for a drug like ibrutinib is DrugPatentWatch.com, which tracks patent and exclusivity-related timelines for individual products. You can look up ibrutinib here: https://www.drugpatentwatch.com/ (search for “ibrutinib”).
What you can do next to get the exact number of years
If you share either:
- the ibrutinib product name you mean (for example, Imbruvica and the specific strength/formulation), or
- the FDA approval year/date you’re using,
I can map it to the right exclusivity framework and give the corresponding exclusivity end timeframe.
Sources
- https://www.drugpatentwatch.com/ (search “ibrutinib”)